EOLS

Evolus Inc

Add to Watchlist

Advanced Chart

7.630

+0.11(1.463%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

7.660

Open

7.490

VWAP

7.54

Vol

472.06K

Mkt Cap

493.55M

Low

7.440

Amount

3.56M

EV/EBITDA(TTM)

Total Shares

62.61M

570.17M

EV/OCF(TTM)

P/S(TTM)

1.72

Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

79.90M

+16.6%

-0.070

-58.82%

91.34M

+15.7%

0.070

+403.6%

67.72M

+10.86%

-0.160

-12.33%

Estimates Revision

The market is revising Downward the revenue expectations for Evolus, Inc. (EOLS) for FY2025, with the revenue forecasts being adjusted by -14.53% over the past three months. During the same period, the stock price has changed by -18.31%.

Revenue Estimates for FY2025

Revise Downward

-14.53%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+324.62%

In Past 3 Month

Stock Price

Go Down

-18.31%

In Past 3 Month

7 Analyst Rating

125.03% Upside

Wall Street analysts forecast EOLS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EOLS is 17.17 USD with a low forecast of 6.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

2 Hold

0 Sell

Moderate Buy

125.03% Upside

Current: 7.630

Low

6.00

Averages

17.17

High

20.00

125.03% Upside

Current: 7.630

Low

6.00

Averages

17.17

High

20.00

H.C. Wainwright

Buy

downgrade

$27 -> $20

2025-08-06

Reason

H.C. Wainwright

Price Target

$27 -> $20

2025-08-06

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Evolus to $20 from $27 and keeps a Buy rating on the shares. The company reset its 2025 outlook amid market softness, the analyst tells investors in a research note.

Needham

Serge Belanger

Buy

Hold

downgrade

$22

2025-08-06

Reason

Needham

Serge Belanger

Price Target

$22

2025-08-06

downgrade

Buy

Hold

Reason

Needham analyst Serge Belanger downgraded Evolus to Hold from Buy and removed the firm's prior $22 price target.

Needham

Buy -> Hold

downgrade

$22

2025-08-06

Reason

Needham

Price Target

$22

2025-08-06

downgrade

Buy -> Hold

Reason

Needham downgraded Evolus to Hold from Buy and removed the firm's prior $22 price target. The company's Q2 revenue was significantly short of consensus due to significant and unforeseen downturn in Jeuveau sales as deteriorating demand caught up with the product, the analyst tells investors in a research note. Worsening consumer sentiment and aesthetic demand led to lower purchase volumes in late Q2, Needham states, adding that the overall negativ macro will continue weighing on consumer sentiment.

BTIG

Sam Eiber

Buy

downgrade

$21 -> $18

2025-08-06

Reason

BTIG

Sam Eiber

Price Target

$21 -> $18

2025-08-06

downgrade

Buy

Reason

BTIG analyst Sam Eiber lowered the firm's price target on Evolus to $18 from $21 and keeps a Buy rating on the shares. Evolus reported a top-line Q2 miss, as Jeuveau sales declined for the first time in company history due to a softening U.S. aesthetic toxin market, the analyst tells investors in a research note. The management also noted they were beginning to see early signs of positive momentum early in Q3, with July incrementally better than the final two weeks of June, the firm is not expecting an immediate rebound, BTIG added.

BTIG

Sam Eiber

Strong Buy

Initiates

$21

2025-04-17

Reason

BTIG

Sam Eiber

Price Target

$21

2025-04-17

Initiates

Strong Buy

Reason

BTIG analyst Sam Eiber initiated coverage of Evolus with a Buy rating and $21 price target. Evolus is a performance beauty company that operates in the cash-pay medical aesthetic market, the analyst tells investors in a research note. The firm says the company's "differentiated go-to-market strategy" as a non-therapeutic, cash-pay company allows it to bypass third-party payer reimbursement dynamics, enabling greater pricing flexibility and the ability to reinvest into provider practices through co-branded marketing initiatives. BTIG sees several paths for Evolus to achieve its goal of at least $700M in revenue and non-GAAP operating income margin of at least 20%.

HC Wainwright & Co.

Douglas Tsao

Strong Buy

Reiterates

$27

2025-04-10

Reason

HC Wainwright & Co.

Douglas Tsao

Price Target

$27

2025-04-10

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Evolus Inc (EOLS.O) is -94.00, compared to its 5-year average forward P/E of -76.49. For a more detailed relative valuation and DCF analysis to assess Evolus Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-76.49

Current PE

-94.00

Overvalued PE

185.79

Undervalued PE

-338.77

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1484.77

Current EV/EBITDA

55.05

Overvalued EV/EBITDA

5150.89

Undervalued EV/EBITDA

-8120.44

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

2.81

Current PS

1.46

Overvalued PS

3.76

Undervalued PS

1.85

Financials

Annual

Quarterly

FY2025Q2

YoY :

+3.70%

69.39M

Total Revenue

FY2025Q2

YoY :

+131.65%

-14.12M

Operating Profit

FY2025Q2

YoY :

+51.03%

-17.14M

Net Income after Tax

FY2025Q2

YoY :

+50.00%

-0.27

EPS - Diluted

FY2025Q2

YoY :

+250.31%

-27.06M

Free Cash Flow

FY2025Q2

YoY :

-8.94%

63.16

Gross Profit Margin - %

FY2025Q2

YoY :

+104.48%

-17.36

FCF Margin - %

FY2025Q2

YoY :

+45.64%

-24.70

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

1.3M

USD

3-6

Months

2.4M

USD

6-9

Months

155.6K

USD

0-12

Months

49.1K

USD

Bought

0-3

393.5K

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

1.0M

Volume

6-9

Months

691.3K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

382.0K

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

1.3M

USD

3-6

Months

2.4M

USD

6-9

Months

155.6K

USD

0-12

Months

49.1K

USD

Bought

0-3

393.5K

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

EOLS News & Events

Events Timeline

2025-08-25 (ET)

2025-08-25

08:10:49

Evolus Reports Successful Achievement of Primary Endpoint in Evolysse Sculpt Trial

2025-08-20 (ET)

2025-08-20

08:02:13

Evolus Files Premarket Approval Application for Evolysse with FDA

2025-08-05 (ET)

2025-08-05

16:23:44

Evolus reports Q2 EPS (27c), consensus (9c)

News

9.0

08-25NASDAQ.COM

Evolus Shares Encouraging Results from Key Study on Evolysse Sculpt for Restoring Mid-Facial Volume

5.0

08-08Newsfilter

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

9.5

08-06SeekingAlpha

Evolus plunges after Q2 miss, guidance cut; Needham downgrades

People Also Watch

Gladstone Capital Corp

Bicara Therapeutics Inc

Lindblad Expeditions Holdings Inc

ChipMOS Technologies Inc

15.715

USD

-1.90%

FAQ

What is Evolus Inc (EOLS) stock price today?

The current price of EOLS is 7.63 USD — it has increased 1.46 % in the last trading day.

EOLS

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

EOLS News & Events

Events Timeline

News

People Also Watch

FAQ

What is Evolus Inc (EOLS) stock price today?

What is Evolus Inc (EOLS)'s business?

What is the price predicton of EOLS Stock?

What is Evolus Inc (EOLS)'s revenue for the last quarter?

What is Evolus Inc (EOLS)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Evolus Inc (EOLS)'s fundamentals?

How many employees does Evolus Inc (EOLS). have?

What is Evolus Inc (EOLS) market cap?